USPTO White Paper Suggests Statutory Factors To Clarify Extent of Statutory Damages for Copyright Infringement
By Salvatore Angotti*
Introduction
Continue Reading
By Salvatore Angotti*
Introduction
Continue Reading
On February 8, 2016, the National Institutes of Health (NIH) responded to Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment’s (UACT) letter requesting that the federal government exercise its authority under the Bayh-Dole Act to break patents on an expensive prostate cancer drug.
In May 2014, the 67th World Health Assembly (WHA) of the World Health Organization (WHO) passed Decision WHA67(15) providing WHO the mandate to explore the feasibility of creating a voluntary pooled fund fund on R&D hosted by the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The Decision outlined three principles guiding the consideration of the pooled fund:
Implications of the Trans Pacific Partnership (TPP) and Regional Comprehensive Economic Partnership (RCEP) on Universal Health Coverage
Knowledge Ecology International
26 January 2016
9 AM to 12:30 PM
Lotus Suite 3. 22nd Floor
Bangkok Convention Centre
Bangkok, Thailand
Today Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) petitioned the Department of Health and Human Services, the Department of Defense, and the National Institutes of Health, asking that they exercise either their royalty-free, non-exclusive license or federal “march-in” rights to end the monopoly on an expensive prostate cancer drug, enzalutamide, marketed as Xtandi by Astellas, a Japanese pharmaceutical company.
Xtandi was invented at UCLA on federal grants from the NIH and DoD.
Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.
This was the release from Representative Doggett’s office:
FOR IMMEDIATE RELEASE
January 11, 2016Contact:
Leslie Tisdale, (202) 225-4865
Over 50 Members of Congress to Obama Administration:
Help End Drug Price Gouging Now
In May 2008, the 61st World Health Assembly (WHA) of the World Health Organization (WHO) adopted the seminal global strategy and plan of action on public health, innovation and intellectual property.
As stated in its aim, the global strategy on public health, innovation and intellectual property serves to
In calendar year 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). This is a large number of approvals.
Attached here is a KEI submission to the US ITC for the January hearing of the
UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, DC
Investigation No. TPA-105-001
Trans-Pacific Partnership Agreement: Likely Impact on the U.S. Economy and on Specific Industry Sectors
Our earlier, related testimony on trade agreements was here: /node/2370